CNS Pharmaceuticals, Inc.

📍 Houston, United States🗓 Founded 2017👥 8 employees💰 Last funded 2018
Biotechnology Research🌐 cnspharma.com
Website LinkedIn
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did CNS Pharmaceuticals, Inc. last raise funding?
The most recent investment in CNS Pharmaceuticals, Inc. recorded on gritt.io was in 2018.
When was CNS Pharmaceuticals, Inc. founded?
CNS Pharmaceuticals, Inc. was founded in 2017.
What industry is CNS Pharmaceuticals, Inc. in?
CNS Pharmaceuticals, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CNS Pharmaceuticals, Inc. based?
CNS Pharmaceuticals, Inc. is headquartered in Houston, United States.